GET DAILY SIGNALSWhy Is Braskem (BAK) Stock Down -44.12% Today?
Key Takeaways
- Shares plunged roughly 44% in Monday's session, falling to about $0.95 from a prior close of $1.70.
- Primary catalyst: Braskem disclosed competing debt-restructuring proposals that would convert billions of dollars of debt into new equity, setting up severe dilution for existing shareholders.
- Secondary driver: An involuntary Chapter 11 petition was filed against financing subsidiary Braskem America Finance Company, raising the risk of a court-supervised outcome.
- Broader context: The decline came amid weakness across Brazilian equities and caution ahead of the Federal Reserve's interest-rate decision.
- Analyst pressure: Recent downgrades from HSBC, UBS, Citi and JPMorgan reflect growing concern about balance-sheet and dilution risk.
- What traders are watching: Restructuring deadlines and the company's next earnings report, currently scheduled for November 12.
- For more context on this stock, explore Price Targets, Earnings, and Forecast pages.
- Discover the strongest-performing automated strategies under current conditions by visiting Trending AI Robots.
Opening Summary
Braskem S.A. (BAK), Latin America's largest petrochemical producer and the Americas' biggest maker of thermoplastic resins and polyolefins, suffered one of its sharpest one-day declines on record Monday. The American depositary receipts fell roughly 44.12%, or about $0.75, to near $0.95, after closing the prior session at $1.70. The selloff was triggered by the company's weekend disclosure of competing restructuring proposals for its approximately $11 billion debt load, terms that investors quickly recognized would leave existing shareholders with only a small fraction of the company.
Debt Restructuring and Dilution Fears
The dominant catalyst behind the share plunge was the release of detailed restructuring documents. Under Braskem's own proposal, creditors would convert about $2.8 billion of debt into equity, while controlling shareholders and third parties would backstop part of a $2.25 billion follow-on share offering. The creditors' counterproposal was similar in shape, calling for roughly $1.85 billion in immediate debt-to-equity conversion alongside a $2.25 billion equity raise, with most of it guaranteed upfront.
Either way, the combined new equity and debt conversion totals roughly $4 billion to $5 billion — many times the company's recent market value of around $650 million. Because the shares being created dwarf the entire existing equity base, current holders of BAK would be diluted to a small minority stake. That arithmetic, not the petrochemical cycle, now drives the stock's valuation, and the market repriced the ADRs accordingly.
Chapter 11 Petition Adds Legal Risk
The dilution concern was compounded by a separate legal front. On October 21, three funds affiliated with hedge fund Bracebridge Capital filed an involuntary Chapter 11 petition against Braskem America Finance Company, a Delaware financing subsidiary that issued roughly $589 million of notes due in 2041. The funds, which say they hold about $272 million of that issue, argue the subsidiary has not been paying debts as they come due.
While the petition targets a financing vehicle rather than the operating company, it signals that not every creditor is willing to wait for a consensual, out-of-court deal. A court-supervised restructuring generally produces a harsher outcome for equity holders than a negotiated settlement, reinforcing the bearish tone in BAK shares.
Analyst Downgrades and Broader Sentiment
The move also reflects a steady stream of negative analyst revisions in recent weeks. HSBC downgraded the stock to Hold, UBS cut it to Sell, Citi moved to Sell, and JPMorgan shifted to Neutral, with several firms citing deteriorating petrochemical spreads, leverage, and the risk that restructuring leaves little value for common shareholders. Monday's selling was further amplified by a generally defensive tone across Brazilian financial and energy names ahead of the Federal Reserve's policy decision, although BAK fell far more than the broader market.
Market Context and Trading Activity
Trading volume was elevated as investors reacted to the weekend disclosures, continuing a pattern of heavy turnover that has accompanied each restructuring headline. The decline pushed the stock decisively below its 50-day moving average and toward the lower end of its 52-week range, which spans roughly $1.40 to $5.40. The move diverged sharply from the broader indices, underscoring that this was a company-specific, balance-sheet-driven repricing rather than a broad market correction.
What Comes Next for BAK
The near-term outlook for BAK hinges on the restructuring negotiations. The parties are working toward an agreement on key terms, with deadlines extending into late October and a final approval window around November 22. A deal that emerges sooner could stabilize sentiment, but only if its terms preserve meaningful value for current holders — a bar that the disclosed proposals, as structured, do not clearly clear.
Investors will also watch the company's next earnings release, expected November 12, for updates on petrochemical spreads, cash flow, and any progress toward finalizing a restructuring plan. Lingering environmental liabilities tied to the Maceió ground-subsidence case, estimated in the billions of dollars, remain a further overhang. Until the capital structure is repaired, volatility in the shares is likely to persist.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of automated trading bots that are currently performing best in live market conditions. Tickeron offers hundreds of AI-driven bots covering thousands of tickers, each varying by strategy, timeframe, performance metrics, and traded symbols. Explore the page to see which strategies are leading the market today.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BAK in downward trend: price dove below 50-day moving average on October 15, 2026
BAK moved below its 50-day moving average on October 15, 2026 date and that indicates a change from an upward trend to a downward trend. In 41 of 44 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BAK as a result. In 64 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BAK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BAK's RSI Indicator exited the oversold zone, 40 of 49 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for BAK just turned positive on October 23, 2026. Looking at past instances where BAK's MACD turned positive, the stock continued to rise in 41 of 46 cases over the following month. The odds of a continued upward trend are 89%.
Following a +8.98% 3-day Advance, the price is estimated to grow further. Considering data from situations where BAK advanced for three days, in 185 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: BAK's P/B Ratio (-0.054) is slightly lower than the industry average of (1.155). P/E Ratio (-0.122) is within average values for comparable stocks, (3.120). Projected Growth (PEG Ratio) (0.030) is also within normal values, averaging (3.769). BAK's Dividend Yield (1.587) is considerably higher than the industry average of (0.135). P/S Ratio (0.051) is also within normal values, averaging (0.578).
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. BAK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BAK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of petrochemicals and other related products
Industry ChemicalsMajorDiversified
Advertisement